Ayako Suzuki1, Nobuo Kashiwagi2, Hiroshi Doi3, Kazunari Ishii4, Katsumi Doi5, Mutsukazu Kitano6, Takenori Kozuka7, Tomoko Hyodo8, Masakatsu Tsurusaki9, Yukinobu Yagyu10, Katsuyuki Nakanishi11. 1. Department of Radiology, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osakasayama-city, Osaka 589-8511, Japan. Electronic address: i.am.sue.1211@med.kindai.ac.jp. 2. Department of Radiology, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osakasayama-city, Osaka 589-8511, Japan. Electronic address: k-nobuo@med.kindai.ac.jp. 3. Department of Radiation Oncology, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osakasayama-city, Osaka 589-8511, Japan. Electronic address: h-doi@med.kindai.ac.jp. 4. Department of Radiology, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osakasayama-city, Osaka 589-8511, Japan. Electronic address: ishii@med.kindai.ac.jp. 5. Department of Otolaryngology, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osakasayama-city, Osaka 589-8511, Japan. Electronic address: kdoi@med.kindai.ac.jp. 6. Department of Otolaryngology, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osakasayama-city, Osaka 589-8511, Japan. Electronic address: mutsukazu-kitano@med.kindai.ac.jp. 7. Department of Radiology, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osakasayama-city, Osaka 589-8511, Japan. Electronic address: Kozuka@med.kindai.ac.jp. 8. Department of Radiology, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osakasayama-city, Osaka 589-8511, Japan. Electronic address: hyoudou@radiol.med.kindai.ac.jp. 9. Department of Radiology, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osakasayama-city, Osaka 589-8511, Japan. Electronic address: mtsuru@dk2.so-net.ne.jp. 10. Department of Radiology, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osakasayama-city, Osaka 589-8511, Japan. Electronic address: y-yagyu@med.kindai.ac.jp. 11. Department of Diagnostic and Interventional Radiology, Osaka International Cancer Institute, Japan. Electronic address: je2k-nkns@asahi-net.or.jp.
Abstract
OBJECTIVE: To report clinical features of bone metastases (BM) from head and neck squamous cell carcinoma (HNSCC). METHODS: Among 772 patients with HNSCC diagnosed at our hospital over 9 years, 30 patients (3.9%) had clinical evidence of BM (24 men and 6 women; mean age: 63 years). We assessed the time interval from the primary diagnosis to BM development, symptoms attributable to BM, presence of distant metastases to other organs, number of BM, sites of BM, morphologic changes on computed tomography (CT) images, treatment for BM, and overall survival (OS). RESULTS: BM at the initial stage were found in 9 patients with HNSCC (30%), and in 21 patients (70%) with HNSCC during the course of the disease. In the later patients, the median time interval from the primary diagnosis was 11.5 months. Nineteen patients (63%) did not have BM-related symptoms, 6 (20%) had pain, 3 (10%) had neurologic symptoms resulting from vertebral or skull metastases, and 2 (7%) had hypercalcemia. Seventeen patients (57%) showed bone-exclusive metastases, and 13 (43%) had distant metastases in other organs. Eleven patients (37%) had monostotic metastases (solitary BM), and 19 patients (63%) had polyostotic metastases (multiple BM). When combined, 9 patients (30%) showed bone-exclusive and monostotic metastases. The most commonly affected site was the thoracolumbar spine, accounting for 34% of total BM, followed by the pelvis (24%), shoulder and thorax (21%), and the extremities (17%). Notably, metastases to bones above the clavicle (craniofacial bones and cervical spine) accounted for only 3% of all bone lesions. CT images showed variable morphologic patterns with osteolytic type in 17 patients (57%), intertrabecular in 7 (23%), osteoblastic in 4 (13%), and mixed in 2 (7%). Systematic chemotherapy for BM was performed in 19 patients and radiotherapy in 18. The median survival time for patients with bone-exclusive and monostotic metastases was significantly longer than that for patients with multi-organ metastases or polyostotic metastases at 18.2 months vs. 5.7 months (p=0.02). Neither chemotherapy nor radiotherapy extended OS. CONCLUSION: Thirty percent of BM cases from HNSCC showed bone-exclusive and monostotic metastases. These patients tended to show a more favorable prognosis than patients with multi-organ metastases or polyostotic metastases.
OBJECTIVE: To report clinical features of bone metastases (BM) from head and neck squamous cell carcinoma (HNSCC). METHODS: Among 772 patients with HNSCC diagnosed at our hospital over 9 years, 30 patients (3.9%) had clinical evidence of BM (24 men and 6 women; mean age: 63 years). We assessed the time interval from the primary diagnosis to BM development, symptoms attributable to BM, presence of distant metastases to other organs, number of BM, sites of BM, morphologic changes on computed tomography (CT) images, treatment for BM, and overall survival (OS). RESULTS: BM at the initial stage were found in 9 patients with HNSCC (30%), and in 21 patients (70%) with HNSCC during the course of the disease. In the later patients, the median time interval from the primary diagnosis was 11.5 months. Nineteen patients (63%) did not have BM-related symptoms, 6 (20%) had pain, 3 (10%) had neurologic symptoms resulting from vertebral or skull metastases, and 2 (7%) had hypercalcemia. Seventeen patients (57%) showed bone-exclusive metastases, and 13 (43%) had distant metastases in other organs. Eleven patients (37%) had monostotic metastases (solitary BM), and 19 patients (63%) had polyostotic metastases (multiple BM). When combined, 9 patients (30%) showed bone-exclusive and monostotic metastases. The most commonly affected site was the thoracolumbar spine, accounting for 34% of total BM, followed by the pelvis (24%), shoulder and thorax (21%), and the extremities (17%). Notably, metastases to bones above the clavicle (craniofacial bones and cervical spine) accounted for only 3% of all bone lesions. CT images showed variable morphologic patterns with osteolytic type in 17 patients (57%), intertrabecular in 7 (23%), osteoblastic in 4 (13%), and mixed in 2 (7%). Systematic chemotherapy for BM was performed in 19 patients and radiotherapy in 18. The median survival time for patients with bone-exclusive and monostotic metastases was significantly longer than that for patients with multi-organ metastases or polyostotic metastases at 18.2 months vs. 5.7 months (p=0.02). Neither chemotherapy nor radiotherapy extended OS. CONCLUSION: Thirty percent of BM cases from HNSCC showed bone-exclusive and monostotic metastases. These patients tended to show a more favorable prognosis than patients with multi-organ metastases or polyostotic metastases.